Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism

• প্রধান লেখক: Yvo J.M. op den Kamp (লেখক), Anne Gemmink (লেখক), Marlies de Ligt (লেখক), Bas Dautzenberg (লেখক), Esther Kornips (লেখক), Johanna A. Jorgensen (লেখক), Gert Schaart (লেখক), Russell Esterline (লেখক), Diego A. Pava (লেখক), Joris Hoeks (লেখক), Vera B. Schrauwen-Hinderling (লেখক), Sander Kersten (লেখক), Bas Havekes (লেখক), Timothy R. Koves (লেখক), Deborah M. Muoio (লেখক), Matthijs K.C. Hesselink (লেখক), Jan Oscarsson (লেখক), Esther Phielix (লেখক), Patrick Schrauwen (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Elsevier, 2022-12-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Objective: SGLT2 inhibitors increase urinary glucose excretion and have beneficial effects on cardiovascular and renal outcomes; the underlying mechanism may be metabolic adaptations due to urinary glucose loss. Here, we investigated the cellular and molecular effects of 5 weeks of dapagliflozin tre...